Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters
| Autor: | Philip J. Johnson, R. Williams, NA Dobbs, Peter Harper, C. Kalayci, M. C. Aldous, EM Metivier |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Cirrhosis Carcinoma Hepatocellular Bilirubin medicine.medical_treatment Neutropenia Gastroenterology chemistry.chemical_compound Pharmacokinetics Internal medicine Carcinoma medicine Humans Aged Hyperbilirubinemia Chemotherapy Dose-Response Relationship Drug business.industry Liver Neoplasms Middle Aged medicine.disease Endocrinology Oncology chemistry Liver Doxorubicin Hepatocellular carcinoma Toxicity Female business Research Article |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | A standard dose of Adriamycin (60 mg m-2) was administered to 30 patients with inoperable hepatocellular carcinoma, 16 of whom were hyperbilirubinaemic (18-37 mumol l-1). The hyperbilirubinaemic patients experienced marked myelosuppression, but only minor symptomatic side-effects. The degree of neutropenia was directly related to the serum bilirubin concentration, but not to any other standard liver test, presence or absence of cirrhosis, or any pharmacokinetic parameter studied including the area under the Adriamycin or adriamycinol concentration-time curve to 48 h or infinity, or the terminal half-life of Adriamycin. The area under the log concentration-time curve was significantly greater for both Adriamycin and adriamycinol in patients who were hyperbilirubinaemic compared to those with normal bilirubin. Whilst hyperbilirubinaemic patients may tolerate a full dose of Adriamycin, we found no evidence that this was associated with a better response rate, which was disappointingly low at only 18%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|